Nilotinib 150mg 1 Capsule [Prescription Required]

TASIGNA Nilotinib 150mg 1 Capsule

INDICATIONS
- Treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Patients who have been treated with nilotinib (Tasigna®) for at least 3 years and have achieved a sustained deep molecular response may be eligible for treatment discontinuation (see sections DOSAGE REGIMEN AND ADMINISTRATION and CLINICAL STUDIES).
- Treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) in adult patients resistant to or intolerant to at least one prior therapy including imatinib. Ph+ CML patients in chronic phase, who have been previously treated with imatinib and whose treatment has been switched to nilotinib (Tasigna®) for at least 3 years and have achieved a sustained deep molecular response may be eligible for treatment discontinuation (see sections DOSAGE REGIMEN AND ADMINISTRATION and CLINICAL STUDIES).
- Treatment of pediatric patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- Treatment of pediatric patients with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior therapy including imatinib.

Place of Origin

Switzerland

Product Usage

TASIGNA CAP 150MG X28

Ingredients

Active Substance: Nilotinib
Excipients:150 mg hard capsules
Capsule content: Lactose monohydrate; Crospovidone; Poloxamer 188; Silica colloidal, anhydrous/Colloidal silicon dioxide; Magnesium stearate
Capsule shell: Gelatin; Titanium dioxide (E 171); Iron oxide, red (E 172), Iron oxide, yellow (E 172)
Printing ink: Shellac; Iron oxide, black (E 172); n-Butyl alcohol; Propylene glycol; Dehydrated ethanol; Isopropyl alcohol; Ammonium hydroxide
Nilotinib
200 mg hard capsules
Capsule content: Lactose monohydrate; Crospovidone; Poloxamer 188; Silica colloidal, anhydrous/Colloidal silicon dioxide; Magnesium stearate
Capsule shell: Gelatin; Titanium dioxide (E 171); Iron oxide, yellow (E 172)
Printing ink: Shellac; Dehydrated alcohol; Isopropyl alcohol; Butyl alcohol; Propylene glycol; Strong ammonia solution; Potassium hydroxide; Titanium dioxide; Industrial methylated spirit; Iron oxide, red (E 172), Iron oxide, black (E172)
Pharmaceutical formulations may vary between countries.

Width

1

Height

1

Depth

1